Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model

Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model

Immune evasion is a major challenge for the development of successful cancer treatments. One of the known mechanisms is the expression of immune checkpoints (ICs)—proteins regulating the immune cells activation. The advent of immunotherapy using monoclonal antibodies (mAbs) to block the immune check...

Full description

Bibliographic Details
Main Authors: Mikolaj Kocikowski, Katarzyna Dziubek, Maciej Parys
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
hyperprogression
hyperprogressive disease
tumour-intrinsic signalling
cancer
immunotherapy
comparative oncology
Online Access:https://www.mdpi.com/2072-6694/12/4/804

Internet

https://www.mdpi.com/2072-6694/12/4/804

Similar Items